FDA panel nod on MRD endpoint could expedite myeloma drug approvals

14 Apr 2024
ImmunotherapyAccelerated ApprovalClinical ResultClinical Study
An FDA advisory committee on Friday voted 12-0 that evidence backs up the use of minimal residual disease (MRD) as a feasible surrogate endpoint in clinical trials of multiple myeloma, potentially facilitating the accelerated approval process for new treatments. If the FDA agrees, the decision could introduce a drug development pathway that allows new myeloma drugs to reach patients more quickly.
The agency's Oncologic Drugs Advisory Committee (ODAC) endorsement follows the evaluation of two separate meta-analyses presented by experts from the University of Miami's Sylvester Comprehensive Cancer Center and I2TEAMM, a group brought together by the International Myeloma Foundation (IMF).
These analyses demonstrated a strong association between MRD negativity (MRD-neg) and improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma patients at the individual level. MRD is a measure of the number of multiple myeloma cells in a patient's bone marrow, and is often used in those who have achieved complete response (CR) to further quantify depth of response to treatment beyond CR.
"To date, many myeloma drug approvals take 9-12 years and must demonstrate a PFS of 5-8 years," the IMF said in a statement following the ODAC vote. With MRD testing as an early endpoint, the group argued that PFS study readouts could be available within 9-12 months, as opposed to 5-plus years.
Correlations to survival
The I2TEAMM said MRD-neg is linked to longer PFS and OS in all treatment modalities, including novel immunotherapies such as CAR-T cells and T-cell engagers. Further, the group said "consistent high individual-patient-level correlations" suggest that an MRDneg-CR rate at 10-5 threshold at nine months can "reasonably likely" predict clinical PFS benefit in relapsed/refractory myeloma, as well as newly diagnosed transplant-eligible and transplant-ineligible patients.
Meanwhile, C. Ola Landgren of the Sylvester Comprehensive Cancer CenterCancer Center presented findings from the EVIDENCE meta-analysis on MRD, a collaborative effort with a number of pharmaceutical companies including Sanofi, Johnson & Johnson, Amgen, Takeda and AbbVie.
Landgren said "the most effective treatments are in the first line," given that up to 35% of patients are lost at each successive line of therapy. However, studies with the currently accepted endpoints of PFS and OS in patients with newly-diagnosed disease "are taking a long time to mature. New effective therapies are unavailable to patients for over 10 years while waiting for studies to mature," he added.
The trouble with ORR
Overall response rate (ORR) is recognised as an intermediate endpoint reasonably likely to predict clinical benefit, but there's a snag – ORRs can be so high with conventional therapies such as RV-d (lenalidomide, bortezomib, and dexamethasone) and D-RVd (daratumumab plus RV-d) that some might argue there's no need for novel treatments in newly diagnosed myeloma patients.
However, ORR only requires 50% reduction in disease, which means patients with residual disease inevitably suffer from relapse or refractoriness. "It is no longer possible to develop new therapies in patients with newly diagnosed multiple myeloma with ORR in the accelerated approval pathway," Landgren said.
More to follow.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.